190 related articles for article (PubMed ID: 37222189)
1. Adjuvant and neoadjuvant approaches in pancreatic cancer.
Conroy T; Lambert A; Ducreux M
Curr Opin Oncol; 2023 Jul; 35(4):326-333. PubMed ID: 37222189
[TBL] [Abstract][Full Text] [Related]
2. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial.
van Dam JL; Verkolf EMM; Dekker EN; Bonsing BA; Bratlie SO; Brosens LAA; Busch OR; van Driel LMJW; van Eijck CHJ; Feshtali S; Ghorbani P; de Groot DJA; de Groot JWB; Haberkorn BCM; de Hingh IH; van der Holt B; Karsten TM; van der Kolk MB; Labori KJ; Liem MSL; Loosveld OJL; Molenaar IQ; Polée MB; van Santvoort HC; de Vos-Geelen J; Wumkes ML; van Tienhoven G; Homs MYV; Besselink MG; Wilmink JW; Groot Koerkamp B;
BMC Cancer; 2023 Aug; 23(1):728. PubMed ID: 37550634
[TBL] [Abstract][Full Text] [Related]
3. Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review.
Mavros MN; Moris D; Karanicolas PJ; Katz MHG; O'Reilly EM; Pawlik TM
JAMA Surg; 2021 Jul; 156(7):663-672. PubMed ID: 33787841
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.
Labori KJ; Lassen K; Hoem D; Grønbech JE; Søreide JA; Mortensen K; Smaaland R; Sorbye H; Verbeke C; Dueland S
BMC Surg; 2017 Aug; 17(1):94. PubMed ID: 28841916
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.
Versteijne E; van Dam JL; Suker M; Janssen QP; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Tienhoven G; van Eijck CHJ;
J Clin Oncol; 2022 Apr; 40(11):1220-1230. PubMed ID: 35084987
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant and neoadjuvant therapies in resectable pancreatic cancer: a systematic review of randomized controlled trials.
D'Angelo FA; Antolino L; La Rocca M; Petrucciani N; Magistri P; Aurello P; Ramacciato G
Med Oncol; 2016 Mar; 33(3):28. PubMed ID: 26883935
[TBL] [Abstract][Full Text] [Related]
8. Primarily resectable pancreatic adenocarcinoma - to operate or to refer the patient to an oncologist?
Piątek M; Kuśnierz K; Bieńkowski M; Pęksa R; Kowalczyk M; Nawrocki S
Crit Rev Oncol Hematol; 2019 Mar; 135():95-102. PubMed ID: 30819452
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma.
Motoi F; Unno M
Jpn J Clin Oncol; 2020 May; 50(5):483-489. PubMed ID: 32083290
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
11. Upfront surgery vs. neoadjuvant therapy for resectable pancreatic cancer: a narrative review of available evidence.
Ratnayake CBB; Roberts KJ; Pandanaboyana S
Chin Clin Oncol; 2022 Feb; 11(1):2. PubMed ID: 35184565
[TBL] [Abstract][Full Text] [Related]
12. Current Treatment of Potentially Resectable Pancreatic Ductal Adenocarcinoma: A Medical Oncologist's Perspective.
de Jesus VHF; Riechelmann RP
Cancer Control; 2023; 30():10732748231173212. PubMed ID: 37115533
[TBL] [Abstract][Full Text] [Related]
13. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer].
Scheufele F; Friess H
Chirurg; 2020 May; 91(5):391-395. PubMed ID: 31965198
[TBL] [Abstract][Full Text] [Related]
14. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis.
Uson Junior PLS; Carvalho L; Fernandes MLC; Botrus G; de Souza Martins R; da Silva EF; Dos Santos SSMB; Taniwaki L; Taranto P; Dutra ACP; de Oliveira Filho JB; Araujo SEA; Moura F
Sci Rep; 2022 Aug; 12(1):13592. PubMed ID: 35948602
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits.
Heinrich S; Lang H
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933761
[TBL] [Abstract][Full Text] [Related]
18. Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma.
Du L; DeFoe M; Ruzinova MB; Olsen JR; Wang-Gillam A
Hematol Oncol Clin North Am; 2015 Aug; 29(4):717-26. PubMed ID: 26226906
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant and neoadjuvant approaches to treat surgically resectable pancreatic cancer.
Keedy VL; Berlin J
Curr Treat Options Oncol; 2006 Sep; 7(5):381-8. PubMed ID: 16904055
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials.
van Dam JL; Janssen QP; Besselink MG; Homs MYV; van Santvoort HC; van Tienhoven G; de Wilde RF; Wilmink JW; van Eijck CHJ; Groot Koerkamp B;
Eur J Cancer; 2022 Jan; 160():140-149. PubMed ID: 34838371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
